FDA grants Priority Review to Roche’s personalised medicine entrectinib

    NEXT STORY
    Basilea reports strong revenue growth and significant pipeline progress for full-year 2018
    PREV STORY
    FDA grants Priority Review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 juni 2020

    author_avatar
    NASDAQ Market News

    Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit

    author_avatar
    NASDAQ Market News

    Press release Biocartis Group NV: Results of the Shareholders’ Meetings held on 8 May 2020

    author_avatar
    NASDAQ Market News